Clinical Trial

A Study of Chios Mastic Water in Dyspepsia

Study acronym: MASTIQUA-D
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Chios mastic is a natural product with strong antimicrobial, anti-inflammatory and antioxidant properties, and well-established benefits for dyspeptic disorders. The aim of the present study is to investigate the effectiveness of a natural aqueous extract of Chios mastic (mastic water), a by-product of Chios mastic processing, in the management of dyspepsia. This will be a 3-month randomized double-blind controlled clinical trial in adults with dyspepsia. Participants will be blindly randomized to an intervention group, which will receive 600 mL/d of a carbonated beverage enriched with Chios mastic water (0.2%), or a control group, which will receive 600 mL/d of an identical placebo beverage with no active ingredients. Participants will be evaluated in terms of anthropometric indices, lifestyle habits, severity of dyspepsia-related gastrointestinal symptoms, quality of life, as well as biochemical markers, both pre- and post-intervention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-27.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT06909890
Lead Sponsor Harokopio University
Conditions Dyspepsia
Enrollment 60 participants
Start Date 2025-07-10
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-15